<DOC>
	<DOCNO>NCT01930240</DOCNO>
	<brief_summary>The primary objective study assess blood profile N-methylnicotinamide ( MNA ) follow administration TRIA-662 ( N-methylnicotinamide Chloride ) . The secondary objective study characterize safety tolerability TRIA-662 assess potential gender-related difference plasma profile MNA . Changes serum lipid parameter particular reference triglyceride , lipoprotein lipase , blood pressure effect also note .</brief_summary>
	<brief_title>The Safety Hypolipidemic Agent Healthy Normal Volunteers</brief_title>
	<detailed_description>A total 20 subject volunteer ( 10 male 10 female ) receive follow treatment administer randomized fashion 2 embed placebo dosage group ( 8 active Males 8 active female 2 placebo male female ) : 1 . DRUG ( Low Dose ) : Single therapeutic dose MNA administer 90 mg oral dose 2 . DRUG ( High Dose ) : Single therapeutic dose MNA administer 270 mg oral dose 3 . PLACEBO : Placebo MNA administer identically appear oral dose Each treatment period consist 3-day two-night confinement cycle admission day 1 , treatment day 1 single dose active placebo discharge 24 hour follow last assessment next morning . A washout period 5 day separate treatment period . Standard biochemical clinical baseline medical background physical examination occur screen Day -1 assess/confirm entry criterion . During treatment period , serial plasma sample ( n=12 ) MNA assay collect treatment day . Safety assessment , include vitals sign ( blood pressure , pulse rate , respiration rate , oral body temperature ) , perform screening , baseline , 4 time throughout treatment period . Physical examination standard clinical laboratory test ( hematology , serum chemistry , urinalysis ) obtain screening , admission treatment period , prior subject 's final discharge study . The Lunch meal dose day identical subject occasion . The pharmacokinetic safety assessment perform specified time prior study MNA administration .</detailed_description>
	<mesh_term>Hypolipidemic Agents</mesh_term>
	<criteria>1 . Good health ( base medical history , physical examination , electrocardiogram , clinical laboratory test ) 2 . Nonsmokers ( refrain tobacco usage , include smokeless tobacco , nicotine patch , etc. , 6 month prior Screening visit ) 3 . Between 18 50 year old ( inclusive ) 4 . Body weight within 20 % desirable weight adult Screening visit 5 . Able execute inform write consent ( informed consent must obtain subject enrollment study . 6 . Willingness abstain alcohol xanthinecontaining food beverage duration treatment period 7 . Willingness remain clinic inpatient portion study 8 . Female subject must nonpregnant either surgically sterile , postmenopausal least 1 year , use acceptable method contraception define oral , implanted , transdermal contraceptive plus one follow barrier method : diaphragm spermicidal cream/jelly use condom sexual partner . 1 . Currently abuse drug alcohol history drug alcohol abuse within past two year 2 . Unwilling unable comply protocol reside study unit study period cooperate fully principal investigator site personnel 3 . Has use 1 ) prescription medication within 14 day prior treatment either treatment period 2 ) , overthecounter ( OTC ) medication , herbal preparation , and/or vitamin within 48 hour prior start study MNA administration either treatment period study . 4 . Has clinically abnormal ECG 5 . Has serum potassium , sodium , calcium , magnesium level within normal limit vital sign clinical laboratory value screen visit deem principal investigator make subject inappropriate candidate study 6 . Has take investigational drug 30 day prior screen visit 7 . Has donate lose unit blood within 30 day prior screen visit 8 . History renal , hepatic , gastrointestinal , cardiovascular , hematologic disease 9 . Serious mental physical illness within past year 10 . Has condition ( ) investigator 's opinion would : ) warrant exclusion study b ) prevent subject complete study 11 . Have positive test hepatitis B surface antigen , hepatitis C antibody , HIV antibody screen 12 . Be female subject positive serum pregnancy test breastfeed screen 13 . Be unable understand verbal and/or write English language certify translation inform consent available 14 . Has history hypersensitivity allergic reaction Niacin Nicotinamide 15 . Has prior exposure MNA 16 . Has Mental capacity limit extent subject provide legal consent understand information regard side effect tolerance study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>